erlotinib has been researched along with gilteritinib in 2 studies
| Studies (erlotinib) | Trials (erlotinib) | Recent Studies (post-2010) (erlotinib) | Studies (gilteritinib) | Trials (gilteritinib) | Recent Studies (post-2010) (gilteritinib) |
|---|---|---|---|---|---|
| 221 | 0 | 180 | 135 | 12 | 132 |
| Protein | Taxonomy | erlotinib (IC50) | gilteritinib (IC50) |
|---|---|---|---|
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 6.76 | |
| Cannabinoid receptor 1 | Rattus norvegicus (Norway rat) | 0.0007 | |
| Leukocyte tyrosine kinase receptor | Homo sapiens (human) | 0.0003 | |
| Tyrosine-protein kinase receptor UFO | Homo sapiens (human) | 0.0035 | |
| Receptor-type tyrosine-protein kinase FLT3 | Homo sapiens (human) | 0.0003 | |
| Transcription factor ETV6 | Homo sapiens (human) | 0.0085 | |
| Echinoderm microtubule-associated protein-like 4 | Homo sapiens (human) | 0.0036 | |
| ALK tyrosine kinase receptor | Homo sapiens (human) | 0.0024 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
| Bharate, SB; Raghuvanshi, R | 1 |
2 other study(ies) available for erlotinib and gilteritinib
| Article | Year |
|---|---|
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases | 2022 |